Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

August 1, 2024

https://www.globenewswire.com/news-release/2024/07/31/2921800/0/en/Avalon-s-Laboratory-Services-MSO-Launches-DNA-Testing-Kit-for-Predisposition-to-Opioid-Addiction.html

FREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out more information, please visit www.dna4addiction.com. Avalon owns a 40% equity interest in LSM.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.